News coverage about Cellectis (NASDAQ:CLLS) has been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellectis earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.8837127782929 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
CLLS has been the topic of a number of recent analyst reports. Zacks Investment Research raised Cellectis from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a report on Tuesday, May 15th. BidaskClub cut Cellectis from a “buy” rating to a “hold” rating in a report on Wednesday, March 21st. Guggenheim started coverage on Cellectis in a report on Friday, March 16th. They issued a “neutral” rating on the stock. ValuEngine raised Cellectis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, Nomura lifted their target price on Cellectis to $73.00 and gave the stock a “buy” rating in a report on Wednesday, March 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $42.00.
Shares of CLLS stock opened at $29.39 on Monday. Cellectis has a 12-month low of $21.25 and a 12-month high of $38.85. The stock has a market capitalization of $1.22 billion, a PE ratio of -10.57 and a beta of 1.88.
Cellectis (NASDAQ:CLLS) last issued its earnings results on Monday, May 7th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.01). Cellectis had a negative return on equity of 37.45% and a negative net margin of 337.45%. The firm had revenue of $8.07 million during the quarter, compared to the consensus estimate of $9.53 million. research analysts anticipate that Cellectis will post -2.67 EPS for the current fiscal year.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.